A Prospective, Multi-Center Evaluation of Corneal Flap Creation Using Cheetah Femtosecond Laser System and Cheetah Patient Interface

The study is a 2-phase, prospective, open-label, comparative (phase II) study design that was chosen for the purpose of optimizing the Cheetah settings (phase I), and evaluating the Cheetah system quality of LASIK flap (phase II).

Study Overview

• Status: Recruiting
• Conditions: Refractive Error
• Intervention / Treatment: Device: Cheetah femtosecond laser and Cheetah patient interface; Device: Cheetah femtosecond laser and cheetah patient interface; Device: IntraLase iFS iFS femtosecond laser and patient interface

Detailed Description

This study is a 3-month, 2-phase, prospective, multicenter, open-label, comparative (phase II), randomized (phase II, 1:1 ratio for right and left eyes) study.

The study will be conducted at up to 5 sites and will include up to 30 treated subjects in phase I and up to 300 treated subjects in phase II to achieve minimum 40 eyes with optimized settings and additional eye data for further device experience.

Subjects will be enrolled in phase I until Cheetah setting optimization is achieved. After setting optimization, and upon medical monitor and principal investigator consensus, phase II of the study may begin.

For phase I, one eye of each subject will be included (worst seeing eye should be preferred). The investigational Cheetah femtosecond laser and Cheetah patient interface (PI) will be used on one eye to create a LASIK flap. Refractive correction via corneal ablation with a commercial excimer laser will be performed at the investigator's discretion, provided there is at least 1.00 D SE of refractive error. If refractive correction is performed on the study eye, the fellow eye may receive standard LASIK treatment, otherwise, fellow eye will remain untreated.

Once five consecutive phase I subjects show good flap lift, per investigator's evaluation, central flap thickness within ±10 µm of planned thickness, flap diameter within ±0.5 mm of planned diameter, and upon medical monitor and principal investigator consensus, phase II may begin.

In phase II both eyes of each subject will be treated. The investigator will use the Cheetah femtosecond laser, with the following possible procedures performed:

1. A comparison between the one and two piece PI with the Cheetah system in both eyes. The eye treated with the one piece PI will be the study eye and the eye treated with the two piece PI will be the control eye.
2. A comparison of commercial iFS femtosecond laser and PI in one eye and the Cheetah femtosecond laser (with the one or two piece PI) on the other eye. The eye treated with the Cheetah femtosecond laser will be the study eye and the eye treated with the commercial iFS femtosecond laser will be the control eye.

All procedures will be performed to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The study eye will be randomized (ratio of 1:1 for right eye and left eye).

Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system shall be used on both eyes).

Over the course of the study, minor prototype device settings/improvements (with no safety implications and without compromising the clinical validity of the study) may be performed to optimize the quality of flap.

• Study Type: Interventional
• Enrollment (Estimated): 350
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Study Contact; Phone Number: 1-669-252-5145; Email: cjones56@its.jnj.com

Study Locations

• India
  • Bangalore
    • Rajajinagar, Bangalore, India, 560010
      • Active, not recruiting
      • Narayana Nethralaya Eye Hospital
  • New Delhi
    • Safdarjung Enclave, New Delhi, India, 110029
      • Recruiting
      • Center For Sight
• Singapore
  • Singapore, Singapore, 308433
    • Recruiting
    • Tan Tock Seng Hospital PTE. LTD.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Phase I of study

INCLUSION CRITERIA

To be considered for enrollment in phase I of the study, subject must:

• Sign an informed consent and HIPAA authorization
• Be at least 18 years of age at the time of study exam
• Have best corrected vision of 20/50 or worse
• Be available for all scheduled follow-up visits (see below)

EXCLUSION CRITERIA

Subject will not be eligible to take part in phase I of the study if subject, use or have:

• Known to be pregnant, breastfeeding or intend to become pregnant during the study.
• Recent ocular (eye) trauma or eye surgery
• A history of or active ophthalmic (eye) disease or abnormality
• Ocular hypertension (high eye pressure) with IOP (eye pressure) greater than 21 mmHg, glaucoma suspect, or are taking medications for these conditions
• A history or current diagnosis of any of the following medical conditions that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency disease, ocular herpes; endocrine disorders including, but not limited to unstable thyroid disorders and diabetes, lupus, and rheumatoid arthritis.
• Cardiac pacemaker, implanted defibrillator or other implanted electronic device
• Taking systemic or inhaled medications that may affect wound healing
• Known sensitivity or inappropriate responsiveness to any of the medications used in the study
• Participating in any other clinical study

Phase II of study

INCLUSION CRITERIA

To be considered for enrollment in phase II of the study, subject must:

• Sign an informed consent and HIPAA authorization
• Be at least 18 years of age at the time of study exam
• Have refractive error and be eligible for commercial LASIK treatment
• Be available for all scheduled follow-up visits (see below)

EXCLUSION CRITERIA

Subject will not be eligible to take part in phase II of the study if subject, use or have:

• Known to be pregnant, breastfeeding or intend to become pregnant during the study.
• Recent ocular (eye) trauma or eye surgery
• A history of or active ophthalmic (eye) disease or abnormality
• Ocular hypertension (high eye pressure) with IOP (eye pressure) greater than 21 mmHg, glaucoma suspect, or are taking medications for these conditions
• A history or current diagnosis of any of the following medical conditions that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency disease, ocular herpes; endocrine disorders including, but not limited to unstable thyroid disorders and diabetes, lupus, and rheumatoid arthritis.
• Cardiac pacemaker, implanted defibrillator or other implanted electronic device
• Taking systemic or inhaled medications that may affect wound healing
• Known sensitivity or inappropriate responsiveness to any of the medications used in the study
• Desire for monovision correction
• Participating in any other clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Investigational; In phase I the investigators will use the investigational Cheetah femtosecond laser and Cheetah patient interface (PI) on one eye to create a LASIK flap (worst seeing eye should be preferred). Refractive correction via corneal ablation with a commercial excimer laser will be performed at the discretion of the investigator.If refractive correction is performed on the study eye, the fellow eye may receive standard LASIK treatment, otherwise, fellow eye will remain untreated.	Device: Cheetah femtosecond laser and Cheetah patient interface; Ophthalmic laser surgical system
Active Comparator: Investigational/Control; In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye). Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes).	Device: IntraLase iFS iFS femtosecond laser and patient interface; Commercial ophthalmic laser surgical system
Active Comparator: Control/Investigational; In phase II, both eyes of each subject will be treated. The investigators will use the commercial Cheetah femtosecond laser and Cheetah two piece PI on one eye, and commercial Cheetah femtosecond laser and investigational Cheetah one piece PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye). Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes).	Device: Cheetah femtosecond laser and cheetah patient interface; Ophthalmic laser surgical system

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cheetah ease of flap lift	Ease of flap lift will be graded on a scale of 1-5 relative to Intralase iFS flap.	Operative day
surface quality	Surface quality will be graded on a scale of 1-5 relative to Intralase iFS flap.	Operative Day
amount of opaque bubble layer (OBL)	Amount of opaque bubble layer will be graded on a scale of 1-5 relative to Intralase iFS flap.	Operative Day

Collaborators and Investigators

• Sponsor: Johnson & Johnson Surgical Vision, Inc.
• Investigators: Study Director: Johnson & Johnson Surgical Vision Clinical Trials, Johnson & Johnson Surgical Vision

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2018
• Primary Completion (Estimated): August 31, 2024
• Study Completion (Estimated): August 31, 2024

Study Registration Dates

• First Submitted: December 27, 2018
• First Submitted That Met QC Criteria: December 27, 2018
• First Posted (Actual): December 28, 2018

Study Record Updates

• Last Update Posted (Actual): April 25, 2024
• Last Update Submitted That Met QC Criteria: April 23, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors
• Other Study ID Numbers: CHTA-103-FLAP

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes